Genenta Science nominates Anthony Marucci for election to its Board as Independent Director and appoints Richard Slansky as CFO

– ITALY, Milan –  Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer, today announced the appointment of Richard Slansky is as CFO and the nomination of Anthony Marucci for election to its Board as an Independent Director, at the next AGM on May 20, 2021.

This follows the announcement in November of the nomination of Dr. Stephen Squinto as Chairman to be effective following AGM approval.

“I am delighted to welcome Richard and Anthony to Genenta, as we continue to enhance our management team and Board. They both have impressive backgrounds in life science and strategic business growth.” said CEO, Pierluigi Paracchi.

He added: “Richard is a deeply experienced finance executive, who has a successful track record in raising funds and managing private and public pre-revenue companies. He will bring significant healthcare and management expertise to our team. Anthony will provide new perspectives as an entrepreneur in the immunotherapy areas and his advice, based on extensive business acumen and industry knowledge, will be invaluable as we further develop Genenta. I look forward to working closely with both of our new colleagues.”

About Richard Slansky

Richard Slansky is an experienced senior executive who has extensive financial leadership experience with P&L accountability in public and private life sciences companies for over 30 years. He was CFO of Biological Dynamics, a private company developing a platform technology to isolate DNA, RNA, proteins, and exosomes from blood, plasma, or serum, from 2018-2020. He was previously CFO of OncoSec Medical, a public company where he managed three registered direct public offerings, and several other companies in the healthcare and technology industries.

Richard Slansky said: “I am excited to be joining Genenta at this critical point for the company as it advances the novel immuno-gene therapy Temferon through clinical development. Temferon has the potential to revolutionize the way we address a broad range of tumors and I look forward to working with the talented and dynamic team at Genenta to bring it toward the market and help patients in desperate need.”

He holds an MBA from the University of Arizona, a BS from the Wharton School at the University of Pennsylvania, and serves on the Board of Directors of several private companies.

About Anthony Marucci

Anthony Marucci is a seasoned life science and public company leader who has raised $1.7 billion in the capital in multiple organizations over his 30 years of experience. He is currently President and CEO of Celldex Therapeutics, the company he co-founded in 2004 and which develops targeted therapeutics, including immunotherapies and other targeted biologics. Before founding Celldex, he was Treasurer at Medarex, from which Celldex was spun out, and he holds an MBA from Columbia University and an MHL from Brown University.

Anthony Marucci said: “It is an honor to be asked to join the Board of Directors of Genenta and play a role in its pioneering scientific work. With a strong and knowledgeable team in place and an exciting product, Temferon, in development, I am confident in our ability to transform the treatment options for patients suffering from devastating cancers.”

About Genenta Science

Genenta is a clinical-stage biotechnology company pioneering the development of proprietary hematopoietic stem cell gene therapies for the treatment of a variety of cancers. Temferon is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages. Temferon, which is under investigation in a Phase I/IIa clinical trial in newly diagnosed Glioblastoma Multiforme patients, is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenge in immuno-oncology. Based in Milan, Italy, and New York, USA, Genenta has raised more than €33.6 million in three separate rounds of financing.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team